CRISPR-Cas9-based target validation for p53-reactivating model compounds

Nature Chemical Biology

Volumn 12, Issue 1, 2016, Pages 22-28

  Wanzel, Michael ^a,b   Vischedyk, Jonas B ^a   Gittler, Miriam P ^d   Gremke, Niklas ^a   Seiz, Julia R ^a   Hefter, Mirjam ^a   Noack, Magdalena ^c   Savai, Rajkumar ^a,b   Mernberger, Marco ^a   Charles, Joël P ^a   Schneikert, Jean ^a   Bretz, Anne Catherine ^a   Nist, Andrea ^a   Stiewe, Thorsten ^a,b  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^c MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP D2 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN MDM2; PROTEIN P53; (5-(2,4-BIS((3S)-3-METHYLMORPHOLIN-4-YL)PYRIDO(2,3-D)PYRIMIDIN-7-YL)-2-METHOXYPHENYL)METHANOL; CISPLATIN; DNA BINDING PROTEIN; FANCD2 PROTEIN, HUMAN; FURAN DERIVATIVE; MDM2 PROTEIN, HUMAN; MORPHOLINE DERIVATIVE; MTOR PROTEIN, HUMAN; NSC 652287; RAD18 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

AMINO TERMINAL SEQUENCE; ARTICLE; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; CROSS RESISTANCE; DNA CROSS LINKING; DNA DAMAGE; DNA REPAIR; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HCT116 CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYSIOLOGY; PROCEDURES; TUMOR SUPPRESSOR GENE;

CISPLATIN; CRISPR-CAS SYSTEMS; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FANCONI ANEMIA COMPLEMENTATION GROUP D2 PROTEIN; FURANS; GENE EXPRESSION REGULATION; GENES, P53; HCT116 CELLS; HUMANS; MOLECULAR TARGETED THERAPY; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-MDM2; TOR SERINE-THREONINE KINASES;

EID: 84950336212     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1965     Document Type: Article

References (46)

1. Pant, V. &Lozano, G. Limiting the power of p53 through the ubiquitin proteasome pathway. Genes Dev. 28, 1739-1751 (2014).
2. Ventura, A. et al. Restoration of p53 function leads to tumour regression in vivo. Nature 445, 661-665 (2007).
3. Martins, C.P., Brown-Swigart, L. &Evan, G.I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323-1334 (2006).
4. Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656-660 (2007).
5. Feldser, D.M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572-575 (2010).
6. Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333-339 (2013).
7. Cheok, C.F., Verma, C.S., Baselga, J. &Lane, D.P. Translating p53 into the clinic. Nat. Rev. Clin. Oncol. 8, 25-37 (2011).
8. Kussie, P.H. et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274, 948-953 (1996).
9. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
10. Khoo, K.H., Verma, C.S. &Lane, D.P. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat. Rev. Drug Discov. 13, 217-236 (2014).
11. Michaelis, M. et al. Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death Dis. 2, e243 (2011).
12. Garnett, M.J. et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
13. Lau, L.M.S., Nugent, J.K., Zhao, X. &Irwin, M.S. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27, 997-1003 (2008).
14. Michaelis, M. et al. Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. Cancer Res. 69, 416-421 (2009).
15. Nieves-Neira, W. et al. DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells. Mol. Pharmacol. 56, 478-484 (1999).
16. Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10, 1321-1328 (2004).
17. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998).
18. Tovar, C. et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl. Acad. Sci. USA 103, 1888-1893 (2006).
19. Enge, M. et al. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15, 171-183 (2009).
20. Hedström, E., Eriksson, S., Zawacka-Pankau, J., Arnér, E.S.J. &Selivanova, G. p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA. Cell Cycle 8, 3584-3591 (2009).
21. Grinkevich, V.V. et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 15, 441-453 (2009).
22. Weilbacher, A., Gutekunst, M., Oren, M., Aulitzky, W.E. &van der Kuip, H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis. 5, e1318 (2014).
23. Zhao, C.Y., Grinkevich, V.V., Nikulenkov, F., Bao, W. &Selivanova, G. Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9, 1847-1855 (2010).
24. Burmakin, M., Shi, Y., Hedström, E., Kogner, P. &Selivanova, G. Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin. Cancer Res. 19, 5092-5103 (2013).
25. Wei, X. et al. A simple statistical test to infer the causality of target/phenotype correlation from small molecule phenotypic screens. Bioinformatics 28, 301-305 (2012).
26. Smurnyy, Y. et al. DNA sequencing and CRISPR-Cas9 gene editing for target validation in mammalian cells. Nat. Chem. Biol. 10, 623-625 (2014).
27. Hsu, P.D., Lander, E.S. &Zhang, F. Development and applications of CRISPR-Cas9 for genome engineering. Cell 157, 1262-1278 (2014).
28. Kasap, C., Elemento, O. &Kapoor, T.M. DrugTargetSeqR: a genomics-and CRISPR-Cas9-based method to analyze drug targets. Nat. Chem. Biol. 10, 626-628 (2014).
29. Charles, J.P. et al. Monitoring the dynamics of clonal tumour evolution in vivo using secreted luciferases. Nat. Commun. 5, 3981 (2014).
30. de Lange, J., Verlaan-de Vries, M. &Teunisse, A.F.A.S. &Jochemsen, A.G. Chk2 mediates RITA-induced apoptosis. Cell Death Differ. 19, 980-989 (2012).
31. Niedernhofer, L.J. et al. The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol. Cell. Biol. 24, 5776-5787 (2004).
32. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584 (2007).
33. Kim, H. &D'Andrea, A.D. Regulation of DNA cross-link repair by the Fanconi anemia/BRCA pathway. Genes Dev. 26, 1393-1408 (2012).
34. Kachnic, L.A. et al. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons. Cancer Lett. 305, 86-93 (2011).
35. Song, I.Y. et al. Rad18-mediated translesion synthesis of bulky DNA adducts is coupled to activation of the Fanconi anemia DNA repair pathway. J. Biol. Chem. 285, 31525-31536 (2010).
36. Park, H.K., Wang, H., Zhang, J., Datta, S. &Fei, P. Convergence of Rad6/Rad18 and Fanconi anemia tumor suppressor pathways upon DNA damage. PLoS ONE 5, e13313 (2010).
37. Williams, S.A., Longerich, S., Sung, P., Vaziri, C. &Kupfer, G.M. The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI. Blood 117, 5078-5087 (2011).
38. Zhang, J., Zhao, D., Wang, H., Lin, C.-J. &Fei, P. FANCD2 monoubiquitination provides a link between the HHR6 and FA-BRCA pathways. Cell Cycle 7, 407-413 (2008).
39. Pickering, A. et al. In vitro FANCD2 monoubiquitination by HHR6 and hRad18. Cell Cycle 12, 3448-3449 (2013).
40. Shen, C. et al. Regulation of FANCD2 by the mTOR pathway contributes to the resistance of cancer cells to DNA double-strand breaks. Cancer Res. 73, 3393-3401 (2013).
41. Guo, F. et al. mTOR regulates DNA damage response through NF-?B-mediated FANCD2 pathway in hematopoietic cells. Leukemia 27, 2040-2046 (2013).
42. Krajewski, M., Ozdowy, P., D'Silva, L., Rothweiler, U. &Holak, T.A. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat. Med. 11, 1135-1156 (2005).
43. Visvader, J.E. &Lindeman, G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-768 (2008).
44. Beck, B. &Blanpain, C. Unravelling cancer stem cell potential. Nat. Rev. Cancer 13, 727-738 (2013).
45. Bertolini, G. et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc. Natl. Acad. Sci. USA 106, 16281-16286 (2009).
46. Meng, X., Wang, X. &Wang, Y. More than 45% of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses. Oncol. Rep. 21, 995-1000 (2009).